Truist Securities maintains Insulet at Hold, raises price target to $160 from $153
Truist Securities kept Insulet at Hold but raised its price target to $160 from $153, a 4.6% increase. This implies a 9.2% upside from the Nov 6 close of $146.51. Recent analyst targets for Insulet range from $165 to $171.
How this was made

The 30-second read
Why it matters
The upgrade could attract short-term buying interest but lacks a strong catalyst.
Market read
A single analyst upgrade with a modest target increase; limited impact on broader market.
What to watch
No new earnings or product news accompanies the target change.
Background
Truist Securities updated its valuation for Insulet, a medical device maker, reflecting a modestly higher outlook.
Market effects
None
None
None
Counterpoint
The price target raise may be overly optimistic given limited new operational data.
Key entities
- CompanyInsulet
Medical device manufacturer (ticker PINS)
- AnalystTruist Securities
Equity research firm providing the price target update
